Translate
Recent News
-
Symposium’23 Program
Program here.
“Innovative drugs & health products,
imaging & theranostics agents –
cell & gene biotherapies”, March 17, 2023, 13:30 -
3e matinée Carnot Star “9-12 Recherche-Industrie” dédiée à l’Imagerie, 17 Mars 2023, 8h30
Programme ici, inscriptions ici, . -
FairEmbo en Afrique : “Ce médecin marseillais sauve des femmes avec des bouts de ficelle”
FairEmbo en Afrique : l’Embolisation-pour-tous franchit une nouvelle étape. Plus d’informations ici. -
Webinar: Discover Radiotheranostics in Nuclear Medicine (15 Sept. 2022)
Plus d’informations ici. -
Le projet EmboBio, développé au CERIMED, a reçu le prix de l’innovation AP-HM 2022
Plus d’informations sur le prix AP-HM de l’innovation 2022 ici. Plus d’informations sur le projet Embobio dans cette vidéo. -
Le CERIMED obtient la double certification ISO 9001:2015 et NF X50-900:2016 pour ses activités de prestation et d’innovation radiologiques et nucléaires pré-cliniques
Le Centre Européen de Recherche en Imagerie Médicale (CERIMED, UMS AMU CNRS 2012) a obtenu le 5 juin 2022 la double certification ISO 9001:2015 et NF-X50-900:2016 pour -
Symposium’21 Program
Program here.
“Innovative drugs & health products,
imaging & theranostics agents –
cell & gene biotherapies” -
VECT-HORUS and CERIMED Announce Collaboration to Support the Development of VECT-HORUS’ Theragnostic Agents
VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration -
FAIR-Embo hopes to spread safe, cheap embolization around the world
We are proud to anounce that Pr Vincent Vidal (Marseille, France), Head of the Experimental Interventional Radiology Laboratory hosted at CERIMED, and colleagues have demonstrated the in vivo feasibility
Last Publications (10/461)
- Goga, A, Soussi, G, Mogenet, A, Habert, P, Fourdrain, A, Naud, R et al.. Single-center retrospective cohort study of lung cancer associated with interstitial lung disease: Prognostic factors and molecular profile. Lung Cancer. 2026;215 :109379. doi: 10.1016/j.lungcan.2026.109379. PubMed PMID:41887129 .
- Duong, QH, Le, TK, Tran, TT, Audebert, S, Camoin, L, Nguyen, NG et al.. HSP27 functional switch drives castration-resistant prostate cancer via mTOR pathway activation, highlighting promising combination therapies. J Exp Clin Cancer Res. 2026; :. doi: 10.1186/s13046-026-03695-6. PubMed PMID:41877198 .
- Cherrak, C, Guerra, X, Panneau, J, Vidal, V, Golzarian, J, Dariane, C et al.. Prostatic artery embolization for benign prostatic hyperplasia: State of the art. Diagn Interv Imaging. 2026; :. doi: 10.1016/j.diii.2026.03.002. PubMed PMID:41866253 .
- Maisons, V, Nassar, N, Cottier, JP, Barbet, C, Sautenet, B, Mercier, E et al.. Reversible cerebral lesions in adult STEC-associated hemolytic uremic syndrome. Kidney Int. 2026;109 (4):798. doi: 10.1016/j.kint.2025.08.047. PubMed PMID:41864670 .
- Baboudjian, M, Sordelli, F, Patard, JJ, Moussi, B, Graffeille, V, Basset, V et al.. Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol. Eur Urol Oncol. 2026; :. doi: 10.1016/j.euo.2026.02.003. PubMed PMID:41813528 .
- Pin, G, Horowitz, T, Guedj, E, Felician, O, Ceccaldi, M, Koric, L et al.. Isolated medial temporal lobe amnesia (MTLA): Predictor of cerebral amyloidosis or marker of phenotype-specific vulnerability?. Rev Neurol (Paris). 2026; :. doi: 10.1016/j.neurol.2026.02.149. PubMed PMID:41775642 .
- Ruimy, A, Agripnidis, T, Panneau, J, Nguyen, J, Tradi, F, Marx, T et al.. A New Generation of Eco-Designed Embolic Agents: Towards Sustainable and Personalized Interventional Radiology. J Pers Med. 2026;16 (2):. doi: 10.3390/jpm16020064. PubMed PMID:41745357 PubMed Central PMC12941600.
- Ranque, S, Laurin, J, Linguraru, MG, Jiang, Z, Loundou, A, Boyer, L et al.. Efficacy and mechanism of supervised adapted physical activity on quality of life for patients with fibromyalgia: single-center, prospective, randomised clinical and neuroimaging study. Sci Rep. 2026;16 (1):5398. doi: 10.1038/s41598-025-33433-5. PubMed PMID:41634061 PubMed Central PMC12886965.
- Gargiulo, M, Di-Rocco, C, Bartoli, A, Habert, P, Soussan, J, Barral, PA et al.. Embolic agents in emergency care: a large retrospective cohort study. CVIR Endovasc. 2026;9 (1):13. doi: 10.1186/s42155-026-00651-5. PubMed PMID:41632442 PubMed Central PMC12868507.
- Chopinet, S, Grégoire, E, Adham, M, Puia-Negulescu, S, Bollon, E, Hardwigsen, J et al.. Right split livers are definitely not marginal grafts: a propensity score analysis of a single centre cohort with very long-term follow-up. HPB (Oxford). 2026; :. doi: 10.1016/j.hpb.2026.01.004. PubMed PMID:41620348 .
Dernières Publications (10/461)
- Goga, A, Soussi, G, Mogenet, A, Habert, P, Fourdrain, A, Naud, R et al.. Single-center retrospective cohort study of lung cancer associated with interstitial lung disease: Prognostic factors and molecular profile. Lung Cancer. 2026;215 :109379. doi: 10.1016/j.lungcan.2026.109379. PubMed PMID:41887129 .
- Duong, QH, Le, TK, Tran, TT, Audebert, S, Camoin, L, Nguyen, NG et al.. HSP27 functional switch drives castration-resistant prostate cancer via mTOR pathway activation, highlighting promising combination therapies. J Exp Clin Cancer Res. 2026; :. doi: 10.1186/s13046-026-03695-6. PubMed PMID:41877198 .
- Cherrak, C, Guerra, X, Panneau, J, Vidal, V, Golzarian, J, Dariane, C et al.. Prostatic artery embolization for benign prostatic hyperplasia: State of the art. Diagn Interv Imaging. 2026; :. doi: 10.1016/j.diii.2026.03.002. PubMed PMID:41866253 .
- Maisons, V, Nassar, N, Cottier, JP, Barbet, C, Sautenet, B, Mercier, E et al.. Reversible cerebral lesions in adult STEC-associated hemolytic uremic syndrome. Kidney Int. 2026;109 (4):798. doi: 10.1016/j.kint.2025.08.047. PubMed PMID:41864670 .
- Baboudjian, M, Sordelli, F, Patard, JJ, Moussi, B, Graffeille, V, Basset, V et al.. Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol. Eur Urol Oncol. 2026; :. doi: 10.1016/j.euo.2026.02.003. PubMed PMID:41813528 .
- Pin, G, Horowitz, T, Guedj, E, Felician, O, Ceccaldi, M, Koric, L et al.. Isolated medial temporal lobe amnesia (MTLA): Predictor of cerebral amyloidosis or marker of phenotype-specific vulnerability?. Rev Neurol (Paris). 2026; :. doi: 10.1016/j.neurol.2026.02.149. PubMed PMID:41775642 .
- Ruimy, A, Agripnidis, T, Panneau, J, Nguyen, J, Tradi, F, Marx, T et al.. A New Generation of Eco-Designed Embolic Agents: Towards Sustainable and Personalized Interventional Radiology. J Pers Med. 2026;16 (2):. doi: 10.3390/jpm16020064. PubMed PMID:41745357 PubMed Central PMC12941600.
- Ranque, S, Laurin, J, Linguraru, MG, Jiang, Z, Loundou, A, Boyer, L et al.. Efficacy and mechanism of supervised adapted physical activity on quality of life for patients with fibromyalgia: single-center, prospective, randomised clinical and neuroimaging study. Sci Rep. 2026;16 (1):5398. doi: 10.1038/s41598-025-33433-5. PubMed PMID:41634061 PubMed Central PMC12886965.
- Gargiulo, M, Di-Rocco, C, Bartoli, A, Habert, P, Soussan, J, Barral, PA et al.. Embolic agents in emergency care: a large retrospective cohort study. CVIR Endovasc. 2026;9 (1):13. doi: 10.1186/s42155-026-00651-5. PubMed PMID:41632442 PubMed Central PMC12868507.
- Chopinet, S, Grégoire, E, Adham, M, Puia-Negulescu, S, Bollon, E, Hardwigsen, J et al.. Right split livers are definitely not marginal grafts: a propensity score analysis of a single centre cohort with very long-term follow-up. HPB (Oxford). 2026; :. doi: 10.1016/j.hpb.2026.01.004. PubMed PMID:41620348 .